Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Université de Montréal
$105,000.00
The efficacy of the external artificial pancreas in regulating blood glucose levels in patients with type 2 diabetes who require insulin therapy to manage their disease.
EF 2016-17
Résumé
Type 2 Diabetes (T2D) is a lifelong disease with epidemic levels. Glucose control (normal sugar in the blood) is essential to prevent and slow the progression of complications such as blindness, kidney failure and heart disease. At the early stages, most patients are treated with oral medications. However, T2D progresses with time to a state of decreased insulin secretion. It is estimated that up to 50% of patients will need the addition of insulin at some point over the course of their disease. Despite the addition of insulin injections, the majority of patients do not reach the recommended glucose levels, at least partly due to the fear of hypoglycemia (low sugar levels). New advances in technology led to the development of the external artificial pancreas (AP). The AP components are: a continuous glucose sensor (to read blood glucose), a pump to infuse insulin and an intelligent software that commands changes in insulin infusion doses based on the sensor readings. Our team has developed an expertise in and has already tested successfully our AP in patients with type 1 diabetes (insulin deficiency at the onset of diabetes); AP resulted in a better glucose control while minimizing the risk of hypoglycemia from intensified insulin treatment. Only one study has so far been published about the use of AP in patients with T2D who are on oral agents showing 20% improvement in glucose control. We propose to study AP efficacy in regulating glucose in patients with T2D who require insulin in their treatment (at least 3 injections/day). We will start with a pilot project to test AP over 24 hours that the participants spend at the research center. The next step will be to test the AP in free-living conditions home over several days. AP performance will be compared with the regular treatment (insulin injections). The eventual aim is to provide a safer (less hypoglycemia), better (less hyperglycemia) and easier (automated glucose control) treatment option for patients with T2D.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
365486
Name
Taleb Nadine M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
The efficacy of the external artificial pancreas in regulating blood glucose levels in patients with type 2 diabetes who require insulin therapy to manage their disease.
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
C-Peptide Levels; Clinical Trials; Continuous Glucose Monitoring System; External Artificial Pancreas; Glucagon Levels; Hyperglycaemia; Hypoglycaemia; Insulin Pumps; Randomized Controlled Cross Over Design; Type 2 Diabetes
Abstract
Type 2 Diabetes (T2D) is a lifelong disease with epidemic levels. Glucose control (normal sugar in the blood) is essential to prevent and slow the progression of complications such as blindness, kidney failure and heart disease. At the early stages, most patients are treated with oral medications. However, T2D progresses with time to a state of decreased insulin secretion. It is estimated that up to 50% of patients will need the addition of insulin at some point over the course of their disease. Despite the addition of insulin injections, the majority of patients do not reach the recommended glucose levels, at least partly due to the fear of hypoglycemia (low sugar levels). New advances in technology led to the development of the external artificial pancreas (AP). The AP components are: a continuous glucose sensor (to read blood glucose), a pump to infuse insulin and an intelligent software that commands changes in insulin infusion doses based on the sensor readings. Our team has developed an expertise in and has already tested successfully our AP in patients with type 1 diabetes (insulin deficiency at the onset of diabetes); AP resulted in a better glucose control while minimizing the risk of hypoglycemia from intensified insulin treatment. Only one study has so far been published about the use of AP in patients with T2D who are on oral agents showing 20% improvement in glucose control. We propose to study AP efficacy in regulating glucose in patients with T2D who require insulin in their treatment (at least 3 injections/day). We will start with a pilot project to test AP over 24 hours that the participants spend at the research center. The next step will be to test the AP in free-living conditions home over several days. AP performance will be compared with the regular treatment (insulin injections). The eventual aim is to provide a safer (less hypoglycemia), better (less hyperglycemia) and easier (automated glucose control) treatment option for patients with T2D.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Taleb, Nadine M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~